TY - JOUR
T1 - Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans
AU - Bialer, M.
AU - Hussein, Z.
AU - Dubrovsky, J.
AU - Raz, I.
AU - Abramsky, O.
PY - 1984
Y1 - 1984
N2 - The pharmacokinetics and bioavailability of valproic acid (VPA) were compared in six healthy volunteers after oral administration of the drug as follows: 1 g in standard tablet form, 1 g in enteric-coated tablet form, and 0.8 g in gelatin-capsule form. Following the administration of standard tablets, VPA concentrations reached a peak mean ± SD of 105.4 ± 9.0 μg/ml at 1 h and declined monoexponentially, with a terminal half-life of 14.9 ± 2.4 h. Following the administration of the capsule, the serum concentration reached a peak of 82.1 ± 14.8 μg/ml at 4 h. Following the administration of an enteric-coated tablet, there was an average time lag of 2 h with a delayed peak serum concentration of 93.5 ± 13.1 μg/ml at 6 h. An identical terminal half-life of VPA was obtained for the three oral formulations. The bioavailability of the three VPA formulations was not significantly different, and it may be concluded that these formulations are bio-equivalent.
AB - The pharmacokinetics and bioavailability of valproic acid (VPA) were compared in six healthy volunteers after oral administration of the drug as follows: 1 g in standard tablet form, 1 g in enteric-coated tablet form, and 0.8 g in gelatin-capsule form. Following the administration of standard tablets, VPA concentrations reached a peak mean ± SD of 105.4 ± 9.0 μg/ml at 1 h and declined monoexponentially, with a terminal half-life of 14.9 ± 2.4 h. Following the administration of the capsule, the serum concentration reached a peak of 82.1 ± 14.8 μg/ml at 4 h. Following the administration of an enteric-coated tablet, there was an average time lag of 2 h with a delayed peak serum concentration of 93.5 ± 13.1 μg/ml at 6 h. An identical terminal half-life of VPA was obtained for the three oral formulations. The bioavailability of the three VPA formulations was not significantly different, and it may be concluded that these formulations are bio-equivalent.
UR - http://www.scopus.com/inward/record.url?scp=0021362216&partnerID=8YFLogxK
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 6421770
AN - SCOPUS:0021362216
SN - 0021-2180
VL - 20
SP - 46
EP - 49
JO - Israel Journal of Medical Sciences
JF - Israel Journal of Medical Sciences
IS - 1
ER -